FIELD: medicine.
SUBSTANCE: dispersing tablets contain as an active ingredient, deferasirox, 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazole-1-yl]benzoic acid or its pharmaceutically acceptable salt in amount 42 to 65 wt % on total mass basis, and a pharmaceutically acceptable excipient applicable for preparation of tablets. There is also described a method for preparing dispersing tablets by wet granulation technique.
EFFECT: dispersing tablets of deferasirox have disintegration time 5 minutes or less.
13 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION AND METHOD FOR DIRECT PRESSING | 2005 |
|
RU2766487C2 |
COMPOSITION AND METHOD OF DIRECT COMPRESSING | 2005 |
|
RU2391097C2 |
METHOD OF OBTAINING COMPOSITIONS BY EXTRUSION OF RESISTANT TO PRESSING PHARMACEUTICAL SUBSTANCES | 2006 |
|
RU2405539C2 |
PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2465900C2 |
DISPERSED TABLETS DEFERASIROKS | 2003 |
|
RU2338532C2 |
NEW PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2779429C2 |
HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | 2015 |
|
RU2705156C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING ALPELISIB | 2015 |
|
RU2690685C2 |
COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE | 2003 |
|
RU2356549C2 |
Authors
Dates
2010-08-20—Published
2005-04-07—Filed